Short Interest in Cardiff Oncology, Inc. (NASDAQ:CRDF) Expands By 6.0%

Cardiff Oncology, Inc. (NASDAQ:CRDF) saw a large increase in short interest during the month of November. As of November 30th, there was short interest totalling 8,180,000 shares, an increase of 6.0% from the November 15th total of 7,720,000 shares. Based on an average trading volume of 1,480,000 shares, the days-to-cover ratio is presently 5.5 days.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Piper Sandler boosted their target price on Cardiff Oncology from $7.00 to $10.00 and gave the stock an “overweight” rating in a report on Friday. Craig Hallum assumed coverage on Cardiff Oncology in a report on Friday, September 6th. They set a “buy” rating and a $8.00 target price for the company. Finally, HC Wainwright decreased their target price on Cardiff Oncology from $14.00 to $13.00 and set a “buy” rating for the company in a report on Friday, November 8th.

Cardiff Oncology Stock Up 19.9 %

NASDAQ CRDF opened at $3.92 on Monday. Cardiff Oncology has a fifty-two week low of $1.27 and a fifty-two week high of $6.42. The business has a 50 day moving average price of $2.89 and a two-hundred day moving average price of $2.61. The stock has a market cap of $200.43 million, a PE ratio of -4.17 and a beta of 1.89.

Insider Activity

In related news, Director Gary W. Pace acquired 350,115 shares of the company’s stock in a transaction dated Wednesday, December 11th. The stock was bought at an average price of $2.60 per share, with a total value of $910,299.00. Following the purchase, the director now directly owns 1,047,876 shares in the company, valued at $2,724,477.60. The trade was a 50.18 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 7.80% of the company’s stock.

Institutional Trading of Cardiff Oncology

Several large investors have recently bought and sold shares of the company. Barclays PLC grew its position in Cardiff Oncology by 291.9% in the third quarter. Barclays PLC now owns 53,089 shares of the company’s stock valued at $141,000 after acquiring an additional 39,542 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Cardiff Oncology by 1.9% during the third quarter. Geode Capital Management LLC now owns 928,232 shares of the company’s stock worth $2,479,000 after buying an additional 17,557 shares in the last quarter. XTX Topco Ltd grew its position in shares of Cardiff Oncology by 44.3% during the third quarter. XTX Topco Ltd now owns 120,384 shares of the company’s stock worth $321,000 after buying an additional 36,947 shares in the last quarter. State Street Corp grew its position in shares of Cardiff Oncology by 3.4% during the third quarter. State Street Corp now owns 832,652 shares of the company’s stock worth $2,223,000 after buying an additional 27,628 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Cardiff Oncology by 11.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 121,293 shares of the company’s stock worth $324,000 after buying an additional 12,503 shares in the last quarter. Institutional investors and hedge funds own 16.29% of the company’s stock.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.